Biotech Values

[mcbio]

ACH-1625 pre-clinical data

http://www.achillion.com/main.aspx?pn=1625Data&fl=l

Dew, can you have a look when you get a chance at the above link, which links directly to some pre-clinical data on ACH-1625? Management mentioned during the conference call that they have put more specific detail on the Web site about ACH-1625, which they believe has the potential to be a best-in-class compound (I realize everyone says that).

In particular, I'm curious as to what you think about their claim that ACH-1625 has >4000 fold selectivity against human proteases, which ACHN believes should make it more tolerable than compounds like telaprevir. Also, do you know how the other PIs, including the IDIX compounds, stack up in terms of selectivity against human proteases?